Figure 4
From: High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma
(A) The progression-free survival (PFS) of 44 advanced-stage ovarian cancer patients undergoing optimal debulking surgery with high- and low-expressed mesothelin (P=0.053). (B) The overall survival of 44 advanced-stage ovarian cancer patients undergoing optimal debulking surgery with high- and low-expressed mesothelin levels (P=0.013). (C) The PFS of 60 advanced-stage ovarian cancer patients undergoing suboptimal debulking surgery with high- and low-expressed mesothelin levels (P=0.001). (D) The OS of 60 advanced-stage ovarian cancer patients undergoing suboptimal debulking surgery with high- and low-expressed mesothelin levels (P=0.001).
